KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) FCF Margin (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 15 years of FCF Margin data on record, last reported at 31.51% in Q4 2025.

  • For Q4 2025, FCF Margin rose 637.0% year-over-year to 31.51%; the TTM value through Dec 2025 reached 25.71%, up 817.0%, while the annual FY2025 figure was 25.71%, 817.0% up from the prior year.
  • FCF Margin reached 31.51% in Q4 2025 per RIGL's latest filing, down from 34.6% in the prior quarter.
  • Across five years, FCF Margin topped out at 208.67% in Q2 2021 and bottomed at 154.53% in Q1 2022.
  • Average FCF Margin over 5 years is 6.6%, with a median of 10.23% recorded in 2023.
  • Peak YoY movement for FCF Margin: surged 29602bps in 2021, then crashed -25185bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 93.41% in 2021, then skyrocketed by 54bps to 42.87% in 2022, then skyrocketed by 59bps to 17.43% in 2023, then surged by 244bps to 25.14% in 2024, then grew by 25bps to 31.51% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 31.51% in Q4 2025, 34.6% in Q3 2025, and 30.03% in Q2 2025.